You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The method builds on a previous technique the group developed to measure transcriptomes and surface proteins from single cells.
The researchers uncovered disease-linked genes that are expressed in certain cells and disease stages and discovered various gene expression modules.
The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.
The ALS Association is committing $3.5 million, including a $1 million commitment from its Greater New York chapter, while the Tow Foundation is contributing $2.5 million.
While the New York Genome Center says whole-genome cancer sequencing is the future, companies already offering such tests are struggling to get paid.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
The companies will offer BGI's DNBseq next-generation sequencing technology along with Gencove's ImputeSeq low-pass sequencing analysis pipeline.
In Science this week: open genetic genealogy databases can lead to the identification of individuals who have not sought testing, and more.
The two papers published today in Science and Cell have implications for both forensics and genetic research.
Initiated the by New York Genome Center Cancer Group, the Polyethnic-1000 project will focus on cancer patients from ethnic minority groups.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.